ClinicalTrials.gg
RecruitingNCT07086521Updated Oct 21, 2026

Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)

A Phase 1 interventional study of ULSC and Placebo in FSHD - Facioscapulohumeral Muscular Dystrophy, sponsored by Restem, LLC.. Recruiting at 1 site in United States. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Restem, LLC. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 21, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States — 8 open to participants now, 13 under way, 1 of them phase 3. Muscular Dystrophy, Facioscapulohumeral · United States.

Planned enrollment
17th of 21
16 · median 51
Started
2025
with 4 others
Phase 1
3 of 32
2 open now
Primary completion
2029-09
later than 9 of 12 live
Registered
30th of 32
by date

Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, this one is the 17th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 9 of the 12 other live ones, and was the 30th registered.

Muscular Dystrophy, Facioscapulohumeral

79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.

Browse Muscular Dystrophy, Facioscapulohumeral studies →

Open to participants now

8 of the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about how an umbilical cord lining-derived stem cell product (ULSC) performs when treating Facioscapulohumeral Muscular Dystrophy (FSHD) 1 or 2. It will assess safety and preliminary efficacy in relieving symptoms of FSHD with ULSC administered in two intravenous (IV) doses of 100 million cells per dose.

The main questions that this study plans to answer are:

  • Is ULSC as safe as placebo (a look-alike saline without cells) in repeated IV infusion?
  • Does ULSC improve symptoms of FSHD after each dose? Researchers will compare ULSC to placebo.

Participants will:

  • Have been diagnosed with FSHD of a Ricci clinical severity score 1.5 or more.
  • Participate in this study for total duration of 21 months with 11 in-person visits and 5 virtual visits.
  • Visit the clinic for a total of 4 IV infusions (260 mL) 3 months apart.
  • Receive 2 doses of ULSC and 2 doses placebo in either of two sequences, as assigned: ULSC first (Day 1 and Month 3) and placebo second (Month 6 and Month 9), or placebo first (Day 1 and Month 3) and ULSC second (Month 6 and Month 9).
  • Return for follow-up visits after each dose and up to 12 months after final dose.
03

Conditions studied

  • FSHD - Facioscapulohumeral Muscular Dystrophy
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants will be ≥15 years old.
  • Diagnosis of genetically confirmed FSHD 1 or FSHD 2.
  • Participants should have a Ricci clinical severity score of ≥1.5 (range is out of 0-10), at screening, and must be independently ambulatory at the time of the study.
  • Participant will have the ability to comply with the requirements of the study, including MRI.
  • All participants of reproductive age/capacity will be required to use adequate , defined as two forms of highly effective contraceptives, with any partners during the study period and for at least three months beyond the study period for safety.
  • Participant will have the ability to understand and provide written .
  • For those participants who are on drug(s) or supplements that may affect muscle function, as determined by the Investigator, participants must be on a stable dose of that drug(s) or supplement for at least 3 months prior to the first dose of study drug and remain on that stable dose for the duration of the study.

    • This includes the following drug category: Immunomodulatory agents, including targeted biological therapies.
    • Exception is rapamycin. (See Exclusion Criteria #10.)
  • Current and up-to-date immunizations.
  • No to MRI.
  • Hematocrit of ≤ 50%
  • Prostate-specific antigen ≤ 4.0 ng/mL (or ≤ 3.0 ng/mL if the participant has a first-degree relative with prostate cancer)
  • Fasting blood glucose \<126 mg/dL

Exclusion criteria

Exclusion Criteria:

  • to study product components including history of hypersensitivity to dimethyl sulfoxide (DMSO).
  • Active cancer or prior diagnosis of cancer within the past year (patients with basal and squamous cell cancer of skin will not be excluded).
  • Any other condition that, in the judgment of the Investigator or Sponsor, would be a to enrollment, study product administration, or follow-up.
  • Treatment with an product within three months prior to randomization.
  • Known active opportunistic or life-threatening infections including (HIV) and or C.
  • Known active or inactive tuberculosis infection.
  • Use of a product that putatively enhances muscle growth or activity on a chronic basis within 4 weeks before baseline
  • Orally administered cytochrome P450 () substrates and multidrug and toxin extrusion (MATE) and organic anion transporter (OAT)3 substrates are not permitted as concomitant therapy. In case of prior use, wash out period will need to be evaluated by investigator.
  • Statin treatment initiation or significant adjustment to statin regimen within 3 months before baseline (stable, chronic statin use is permissible).
  • Rapamycin treatment within 3 months before baseline.
  • Evidence of an alternative diagnosis other than FSHD or a coexisting myopathy or dystrophy, based on prior muscle or other available investigations.
  • Muscle biopsy within 30 days before baseline.
  • A systolic blood pressure over 160 or a diastolic pressure over 100
  • Heavy alcohol use (greater than 50g/day)
  • Current testosterone or HGH use
  • Current use of medications that interfere with the growth hormone or gonadal endocrine axis.
  • Pregnant of lactating participants.
  • Concomitant severe cardiac, pulmonary disease, active infection, or other conditions that preclude assessment of safety and efficacy of the study product.
  • Anticipated need for surgery during the trial period.
  • A history of prevalent noncompliance with medical therapy.
  • Recipient of an organ transplant.
  • Neutropenia ( \<1,800/mm\^3 [or \<1,000/mm\^3 in African-American participants]).
  • Severe impairment in renal function (estimated \<30 ml/min/1.73m\^2).
  • Recent of planned use of vaccination with live attenuated viruses.
  • Condition that would impair an assessment of muscle strength, including neurological disorders such as Parkinson's disease or severe musculoskeletal condition.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Group 1: ULSC first; Placebo second

    Group 1 will receive a dose of 1 x 10\^8 ULSC through IV administration on Day 1 and Month 3 (two doses, 2 x 10\^8 ULSC in total from both doses). They will then cross-over to Placebo IV administrations on Month 6 and Month 9.

    Biological: ULSC · Biological: Placebo

  • Experimental
    Group 2: Placebo first; ULSC second

    Group 2 will receive Placebo IV administrations on Day 1 and Month 3. They will then cross-over to receive 1 x 10\^8 ULSC IV administrations on Month 6 and Month 9 (2 x 10\^8 ULSC in total).

    Biological: ULSC · Biological: Placebo

Interventions

  • BiologicalULSC

    Allogeneic umbilical-cord lining stem cells (ULSC) are cryopreserved and supplied in vials to be thawed and prepared for infusion at point of use. Each dose of 1 x 10\^8 ULSC will be added into 250 sterile saline for infusion (total volume of 260 mL volume).

  • BiologicalPlacebo

    The Placebo will consist of 250 ml of sterile saline with sterile diluent solution added (total volume of 260 mL) for IV administration.

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE) and Serious Adverse Events (SAEs) that begin during or following treatment infusion.

    Cumulative listing of all AEs/SAEs with descriptive statistics for categorical variables and count variables with emphasis on all SAEs and AEs/SAEs suspected to be treatment infusion-related.

    Time frame: Baseline, during each infusion, 7 days, 30 days, and 3 months after each infusion, as well as 6 months and 12 months after the final dose.

Secondary outcomes

  1. Balance and Mobility Assessment of Timed Up and Go (TUG)

    Individuals are asked to rise from a chair, walk 3 meters, turn around, return to the chair, and sit. The time that it takes to complete the task will be recorded. The TUG will be performed at a comfortable pace and at a maximum pace. Assistive devices, orthoses, and ankle braces will be allowed. This test involves walking only, not running or skipping. This test is a timed test, and it will use Stanford-created OPENCAP video capture system.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  2. Leg Function Assessment of Timed Sit to Stand

    Timed sit to stand tests proximal lower extremity strength and core strength by having subjects stand from a standard height chair. This will be performed and timed one time and five times; the latter using Stanford-created OPENCAP video capture system.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  3. Leg Function Assessment of 10 Meter Walk (10MWT)/Run (10MWRT)

    From a standing start, the participant will be asked to go 10 meters either walking at normal speed (10MWT) or as quickly as possible, whether by walking or running (10MWRT). Orthotics and ankle braces are allowed. The time in seconds to complete the task will be recorded; these tests will use Stanford-created OPENCAP video capture system.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  4. Leg Function Assessment of Time to Ascend/Descend 4 Stairs

    Participants will be asked to climb up and down (Timed as separate tests) 4 stairs as quickly as possible, using steps with a six-inch rise and ten-inch run. Quality grades will be captured for this test to record the use of railings and manner of ascent (i.e. step-to or step-over-step pattern). The time it takes to complete the task will be recorded.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  5. Leg Function Assessment of Toe Stand

    Evaluate lower leg and balance by having participants rise onto tip toes as quickly as possible and try and hold it there for 30 seconds. This test will use Stanford-created OPENCAP video capture system.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 (6 months after the final dose).

  6. Leg Function Assessment of Jumping

    To evaluate participant's ability to jump as high as possible. If unable to jump, the participant is instructed to simulate a jump by bending their knees and standing upright as fast as they can. This test will use Stanford-created OPENCAP video capture system.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  7. Shoulder and Arm Function Assessment Using Brooke Upper Extremity Scale (with and without weights)

    The tasks are an adaptation of the activities contained in the Brooke upper extremity scale, to test straight arm abduction without compensation to lift hands above head, or to test ability to lift a weighted cup (200 g) to chin or alternatively, to lift an unweighted cup. This category tests proximal to mid arm tasks, and the ability to coordinate upper extremity function across a variety of muscle groups (shoulder abduction/flexion, elbow flexion/extension). Brooke score is assigned on scale from 2 (unable to lift unweighted cup from lap to chin) to 6 (hands lifted above head with no compensation). This test will use Stanford-created OPENCAP video capture system.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  8. Shoulder and Arm Function Assessment of Donning and Doffing a Coat

    Measuring the time it takes participants to don and doff a coat, which is a more complex task that incorporates functional use of both proximal and mid-limb muscles.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  9. Shoulder and Arm Function Assessment of Stacking Heavy Cans

    Assessing participant's ability and number to stack up to five (5) heavy cans.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  10. Manual Muscle Testing (MMT) of Shoulder and Elbow Muscle Groups

    These tests evaluate right and left separately tested movements including shoulder abduction, shoulder forward flexion, and elbow flexion. Tests will include use of a 5-pound weight and evaluate whether participant can perform movements with full range of motion (ROM) and no compensation for the best score on the scale. In each test, score is determined based on defined criteria, such as the ability to perform with compensation or without weight (antigravity), with or without compensation, or with limited degree of range of motion.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  11. Assessment of Arm Range of Motion (ArmRoM)

    This task evaluates bilateral arm movement in six (6) directions, arm raises in different directions and horizontal sweeps at waist height or as high as able, to assess range of motion of shoulder muscle groups and ability to move arms in smooth controlled way while trying not to bend elbows. This test will use Stanford-created OPENCAP video capture system.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  12. Shoulder and Arm Function Assessment of Curls

    This task evaluates elbow and wrist movement, including elbow full extension, elbow full flexion, and wrist supinated and pronated RoM while keeping elbows at 90° and moving in smooth controlled way. This test will use Stanford-created OPENCAP video capture system.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  13. Trunk Function Assessment of Picking up a Penny or Pencil from the Floor

    Picking up a penny or pencil off the floor tests the ability to bend and straighten but also balance and the ability of lower extremity muscles to compensate for core weakness.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  14. Trunk Function Assessment of Sitting Up from Supine and Timed Supine to Sit

    The ability to sit up from lying supine and the timed supine to sitting at edge of bed test reflects core muscle strength and coordination. Functional axial strength will be assessed by instructing individuals to move from supine to sitting on the edge of a plinth as quickly as possible. The time that it takes to complete the task will be recorded, as well as the manner of sitting (e.g. using one or two hands to pull up).

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).

  15. Quantitative Muscle Testing (QMT) with Hand-Held Dynamometry (HHD)

    QMT will be conducted by trained and study qualified clinical evaluator, with specific procedures as described in the Clinical Evaluator Manual, and using Microfet Handheld Myometer. Shoulder abductors, elbow flexors, elbow extensors, knee flexors, and hand grip force will be evaluated bilaterally and data (kg) will be recorded for each. Each assessment is obtained three times, for 5 seconds each attempt and 10 seconds of rest between each attempt. Every effort should be made to have the same evaluator conduct these tests for an individual participant during the study.

    Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 (6 months after the final dose).

  16. Muscle Fat Fraction (MFF)

    Change from baseline in Muscle Fat Fraction (MFF, %) as a measure of infiltration of fat in muscle; this is assessed by Musculoskeletal (MSK) Magnetic Resonance Imaging (MRI)

    Time frame: Baseline, Month 6 and Month 12.

  17. Lean Muscle Volume (LMV)

    Change from baseline in Lean Muscle Volume (LMV, cu cm or Liter) as a measure of infiltration of fat in muscle; this is assessed by Musculoskeletal (MSK) Magnetic Resonance Imaging (MRI).

    Time frame: Baseline, Month 6 and Month 12.

  18. Physical Activity Monitor (Actigraphy Wearable Device)

    At prespecified times for at least 30 days, exercise and sleep activity is monitored using the Actigraphy wearable device, providing real-world assessment of physical activity, sleep, functional mobility, and vital signs.

    Time frame: After screening and before Day 1 (baseline), 30 days before Month 6 (cross-over), 30 days before Month 12, and 30 days before Month 15 (end of study).

  19. Ricci Clinical Severity Score

    To assess clinical severity of disease on a 10-point scale score, 0 implying no muscle weakness and 10 implying wheelchair dependency.

    Time frame: Screening, Day 1, Month 6, Month 12, and Month 15

  20. Patient-Reported Quality of Life Outcome Assessed by Activity Limitations for Patients with Upper and/or Lower Limb Impairments (ACTIVLIM)

    Change in patient-reported quality of life by using ACTIVLIM 18-item questionnaire (total score scale from 0 to 36) that assess activity limitations of daily living with higher score indicating better function.

    Time frame: Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).

  21. Patient-Reported Quality of Life Outcome Assessed by 5-Level EQ-5D Version (EQ-5D-5L)

    Change in patient-reported quality of life by using EQ-5D-5L, which is a standardized measure of health status developed by the EuroQol Group. EQ-5D-5L covers the following five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; the five levels of severity range from no problems to extreme problems. In addition, it provides Visual Analog Scale (VAS) for patient self-assessment of health with VAS 100 score ranging from 0 to 100. Scoring the EQ-5D-5L produces a health state profile index score in which 1 is the best possible health state.

    Time frame: Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).

  22. Patient-Reported Disease Activity & Quality of Life Outcomes Assessed by Domain Delta

    Change in level of disease activity as reflected by patient-reported disease and quality of life outcomes by using Domain Delta 14-item questionnaire, which inquires about the patient's self-assessed perception of change in 14 subdomains including overall health, quality of life, fatigue, pain, subdomains of physical function, and various subdomains that include thinking, satisfaction/performance in social situations, and communication. Participants evaluate their own perceived change on a 5-level scale with scores ranging from "a lot worse" to "a lot better". The Domain Delta is an instrument developed to assess quality of life and how disease has changed since last visit.

    Time frame: Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).

  23. Patient-Reported Quality of Life Outcome Assessed by PROMIS-57

    Change in level of disease activity as reflected in patient-reported quality of life outcome assessed by using PROMIS-57. The PROMIS-57 is a questionnaire developed by the NIH PROMIS initiative that generates scores for physical function and the impact of physical limitations on daily life.

    Time frame: Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).

  24. Patient-Reported Pain Assessed by Visual Analogue Scale (VAS 10)

    Change in level of patient-reported pain using Visual Analogue Scale (VAS 10) with 0 being no pain and 10 being the worst pain.

    Time frame: Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).

  25. Patient-Reported Disease Activity & Quality of Life Outcomes Assessed by Upper Extremity Functional Index 15 (UEFI-15)

    Change in level of disease activity as reflected by patient-reported disease and quality of life outcomes by using UEFI-15. The UEFI-15 is a validated patient reported measure for adults with upper extremity dysfunction involving a 15-item questionnaire that assesses patient-reported level of difficulty in performing activities of daily living using upper extremities and provides a score ranging from 0.0 to 100.0 with 100.0 indicating the highest functional status.

    Time frame: Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).

  26. Patient-Reported Disease Activity & Quality of Life Outcomes Assessed by Facial Disability Index (FDI) for physical facial function

    Change in level of disease activity as reflected by patient-reported disease and quality of life outcomes by using FDI. The FDI physical score is a short 5 item questionnaire which assesses the physical impact of facial weakness. The responses are individually scored on a scale of 0 to 5 for physical function, and on a scale of 0 to 6 for social function; total scores that are then converted into a percentage scale. A score of 100% represents normal function with no difficulty or impact, and lower scores indicate increasing levels of disability with higher levels of difficulty and impact.

    Time frame: Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).

  27. Timed Motor Function Tests

    To evaluate changes from baseline in timed motor function tests.

    Time frame: Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).

Other outcomes

  1. Tissue Oxygenation Assessed by Near Infrared Spectroscopy (NIRS) during Cardiopulmonary Exercise Testing (CPET)

    Change from baseline of tissue oxygenation during Cardiopulmonary Exercise Testing (CPET) using Near Infrared Spectroscopy (NIRS) to monitor regional tissue oxygenation (rSO2) by detecting differential light absorption by oxygenated and deoxygenated hemoglobin.

    Time frame: Between Screening, Day 1, Month 6 and Month 12.

  2. Functional and Quantitative Assessments

    Change from baseline for various functional and quantitative assessments.

    Time frame: At each clinical visit up to Month 15 end of study (6 months after final dose).

  3. Inflammatory and Immune Markers

    Changes in the levels of cytokines and other inflammatory and immune biomarkers measured in plasma samples.

    Time frame: From baseline to 30 days and to 3 months after each infusion, up to Month 6 (prior to first dose at cross-over), and Month 12 (6 months after cross-over), as well as Month 15 end of study (6 months after final dose).

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2025 (actual). Primary completion is estimated for Sep 2029, 45 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Sep 2028 → Sep 2029 and completion Mar 2029 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 25, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Sep 2029was Sep 2028
CompletionEst.
Mar 2030was Mar 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2028→Sep 2029
Oct 21, 2026
Study completion
Mar 2029→Mar 2030
Oct 21, 2026
Eligibility
4 inclusion criteria edited, 1 added, 2 removed; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedDiagnosis of genetically confirmed FHSDFSHD 1 or FSHD 2.
  • EditedParticipants should have a Ricci clinical severity score of ≥31.5 (range is out of 0-10), at screening, and must be independently ambulatory at the time of the study.
  • EditedFor those participants who are on drug(s) or supplements that may affect muscle function, as determined by the Investigator, participants must be on a stable dose of that drug(s) or supplement for at least 3 months prior to the first dose of study drug and remain on that stable dose for the duration of the study. This includes the following drug category:
  • EditedoThis includes the following drug category: Immunomodulatory agents, including targeted biological therapies.
  • RemovedReduced upper arm strength as measured by the Performance of Upper Limb score of ≤5.
  • AddedException is rapamycin. (See Exclusion Criteria #10.)
  • RemovedTotal relative reachable surface area (RSA) (Q1-Q4) without weight in the dominant upper extremity assessed by reachable workspace (RWS) ≥ 0.2 and ≤ 0.7.
Exclusion criteria
  • EditedOrally administered cytochrome P450 (CYP3A4) substrates and multidrug and toxin extrusion (MATE) and organic anion transporter (OAT)3 substrates are not permitted as concomitant therapy. In case of prior use, wash out period will need to be evaluated by investigator.
  • EditedSevere impairment in renal function (estimated glomerular filtration rate <30 ml/kg*min/1.73m\^2).
Oct 21, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameAdverse Events (AE) and Serious Adverse Events (SAEs) that begin during or following treatment infusion.7 days and 30 days after each infusion, as well as 6 months after the final dose for each period (Month 9 and Month 15). → Baseline, during each infusion, 7 days, 30 days, and 3 months after each infusion, as well as 6 months and 12 months after the final dose.
  • DescriptionAdverse Events (AE) and Serious Adverse Events (SAEs) that begin during or following treatment infusion.: how it is measured was reworded
Oct 21, 2026
Secondary outcomes
1 edited, 8 time frame changed, 18 added, 1 removed, 2 description edited, 8 more
What changed in the outcomes
  • EditedPatient-Reported Disease Activity & Quality of Life Outcomes Assessed by Upper Extremity Functional Index 15 (UEFI-15)Time frame: Between baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
  • AddedBalance and Mobility Assessment of Timed Up and Go (TUG)Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedLeg Function Assessment of Timed Sit to StandTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedLeg Function Assessment of 10 Meter Walk (10MWT)/Run (10MWRT)Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedLeg Function Assessment of Time to Ascend/Descend 4 StairsTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedLeg Function Assessment of Toe StandTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 (6 months after the final dose).
  • AddedLeg Function Assessment of JumpingTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedShoulder and Arm Function Assessment Using Brooke Upper Extremity Scale (with and without weights)Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedShoulder and Arm Function Assessment of Donning and Doffing a CoatTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedShoulder and Arm Function Assessment of Stacking Heavy CansTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedManual Muscle Testing (MMT) of Shoulder and Elbow Muscle GroupsTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedAssessment of Arm Range of Motion (ArmRoM)Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedShoulder and Arm Function Assessment of CurlsTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedTrunk Function Assessment of Picking up a Penny or Pencil from the FloorTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedTrunk Function Assessment of Sitting Up from Supine and Timed Supine to SitTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
  • AddedQuantitative Muscle Testing (QMT) with Hand-Held Dynamometry (HHD)Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 (6 months after the final dose).
  • AddedPhysical Activity Monitor (Actigraphy Wearable Device)Time frame: After screening and before Day 1 (baseline), 30 days before Month 6 (cross-over), 30 days before Month 12, and 30 days before Month 15 (end of study).
  • AddedRicci Clinical Severity ScoreTime frame: Screening, Day 1, Month 6, Month 12, and Month 15
  • AddedTimed Motor Function TestsTime frame: Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
  • RemovedFacioscapulohumeral Muscular Dystrophy Composite Outcome Measure (FSHD-COM)Time frame: Baseline, 7, and 30 days after each infusion, as well as 6 months after the final dose for each period (Month 9 and Month 15).
  • Time frameMuscle Fat Fraction (MFF)Baseline to Month 6 and Month 12. → Baseline, Month 6 and Month 12.
  • Time frameLean Muscle Volume (LMV)Baseline to Month 6 and Month 12. → Baseline, Month 6 and Month 12.
  • Time framePatient-Reported Quality of Life Outcome Assessed by PROMIS-57Between baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
  • Time framePatient-Reported Pain Assessed by Visual Analogue Scale (VAS 10)Between baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
  • Time framePatient-Reported Quality of Life Outcome Assessed by Activity Limitations for Patients with Upper and/or Lower Limb Impairments (ACTIVLIM)Between baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
  • Time framePatient-Reported Quality of Life Outcome Assessed by 5-Level EQ-5D Version (EQ-5D-5L)Between baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
  • Time framePatient-Reported Disease Activity & Quality of Life Outcomes Assessed by Domain DeltaBetween baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
  • Time framePatient-Reported Disease Activity & Quality of Life Outcomes Assessed by Facial Disability Index (FDI) for physical facial functionBetween baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
  • DescriptionPatient-Reported Disease Activity & Quality of Life Outcomes Assessed by Domain Delta: how it is measured was reworded
  • DescriptionPatient-Reported Disease Activity & Quality of Life Outcomes Assessed by Facial Disability Index (FDI) for physical facial function: how it is measured was reworded
  • …and 8 more, on the record history on ClinicalTrials.gov ↗
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Primary completion Sep 2028→Sep 2029
    Study completion Mar 2029→Mar 2030
    Eligibility 4 inclusion criteria edited, 1 added, 2 removed; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedDiagnosis of genetically confirmed FHSDFSHD 1 or FSHD 2.
    • EditedParticipants should have a Ricci clinical severity score of ≥31.5 (range is out of 0-10), at screening, and must be independently ambulatory at the time of the study.
    • EditedFor those participants who are on drug(s) or supplements that may affect muscle function, as determined by the Investigator, participants must be on a stable dose of that drug(s) or supplement for at least 3 months prior to the first dose of study drug and remain on that stable dose for the duration of the study. This includes the following drug category:
    • EditedoThis includes the following drug category: Immunomodulatory agents, including targeted biological therapies.
    • RemovedReduced upper arm strength as measured by the Performance of Upper Limb score of ≤5.
    • AddedException is rapamycin. (See Exclusion Criteria #10.)
    • RemovedTotal relative reachable surface area (RSA) (Q1-Q4) without weight in the dominant upper extremity assessed by reachable workspace (RWS) ≥ 0.2 and ≤ 0.7.
    Exclusion criteria
    • EditedOrally administered cytochrome P450 (CYP3A4) substrates and multidrug and toxin extrusion (MATE) and organic anion transporter (OAT)3 substrates are not permitted as concomitant therapy. In case of prior use, wash out period will need to be evaluated by investigator.
    • EditedSevere impairment in renal function (estimated glomerular filtration rate <30 ml/kg*min/1.73m\^2).
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameAdverse Events (AE) and Serious Adverse Events (SAEs) that begin during or following treatment infusion.7 days and 30 days after each infusion, as well as 6 months after the final dose for each period (Month 9 and Month 15). → Baseline, during each infusion, 7 days, 30 days, and 3 months after each infusion, as well as 6 months and 12 months after the final dose.
    • DescriptionAdverse Events (AE) and Serious Adverse Events (SAEs) that begin during or following treatment infusion.: how it is measured was reworded
    Secondary outcomes 1 edited, 8 time frame changed, 18 added, 1 removed, 2 description edited, 8 more
    What changed in the outcomes
    • EditedPatient-Reported Disease Activity & Quality of Life Outcomes Assessed by Upper Extremity Functional Index 15 (UEFI-15)Time frame: Between baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
    • AddedBalance and Mobility Assessment of Timed Up and Go (TUG)Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedLeg Function Assessment of Timed Sit to StandTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedLeg Function Assessment of 10 Meter Walk (10MWT)/Run (10MWRT)Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedLeg Function Assessment of Time to Ascend/Descend 4 StairsTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedLeg Function Assessment of Toe StandTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 (6 months after the final dose).
    • AddedLeg Function Assessment of JumpingTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedShoulder and Arm Function Assessment Using Brooke Upper Extremity Scale (with and without weights)Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedShoulder and Arm Function Assessment of Donning and Doffing a CoatTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedShoulder and Arm Function Assessment of Stacking Heavy CansTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedManual Muscle Testing (MMT) of Shoulder and Elbow Muscle GroupsTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedAssessment of Arm Range of Motion (ArmRoM)Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedShoulder and Arm Function Assessment of CurlsTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedTrunk Function Assessment of Picking up a Penny or Pencil from the FloorTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedTrunk Function Assessment of Sitting Up from Supine and Timed Supine to SitTime frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 end of study (6 months after the final dose).
    • AddedQuantitative Muscle Testing (QMT) with Hand-Held Dynamometry (HHD)Time frame: Baseline, and at 30 days and 3 months after each infusion, as well as at Month 15 (6 months after the final dose).
    • AddedPhysical Activity Monitor (Actigraphy Wearable Device)Time frame: After screening and before Day 1 (baseline), 30 days before Month 6 (cross-over), 30 days before Month 12, and 30 days before Month 15 (end of study).
    • AddedRicci Clinical Severity ScoreTime frame: Screening, Day 1, Month 6, Month 12, and Month 15
    • AddedTimed Motor Function TestsTime frame: Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
    • RemovedFacioscapulohumeral Muscular Dystrophy Composite Outcome Measure (FSHD-COM)Time frame: Baseline, 7, and 30 days after each infusion, as well as 6 months after the final dose for each period (Month 9 and Month 15).
    • Time frameMuscle Fat Fraction (MFF)Baseline to Month 6 and Month 12. → Baseline, Month 6 and Month 12.
    • Time frameLean Muscle Volume (LMV)Baseline to Month 6 and Month 12. → Baseline, Month 6 and Month 12.
    • Time framePatient-Reported Quality of Life Outcome Assessed by PROMIS-57Between baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
    • Time framePatient-Reported Pain Assessed by Visual Analogue Scale (VAS 10)Between baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
    • Time framePatient-Reported Quality of Life Outcome Assessed by Activity Limitations for Patients with Upper and/or Lower Limb Impairments (ACTIVLIM)Between baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
    • Time framePatient-Reported Quality of Life Outcome Assessed by 5-Level EQ-5D Version (EQ-5D-5L)Between baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
    • Time framePatient-Reported Disease Activity & Quality of Life Outcomes Assessed by Domain DeltaBetween baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
    • Time framePatient-Reported Disease Activity & Quality of Life Outcomes Assessed by Facial Disability Index (FDI) for physical facial functionBetween baseline and the 6-month timepoint (prior to third administration), and between the 6-month and 12-month timepoints. → Between baseline and timepoints up to Month 6 (prior to first dose at cross-over), between Month 6 and timepoints up to Month 12, and at Month 15 end of study (6 months after final dose).
    • DescriptionPatient-Reported Disease Activity & Quality of Life Outcomes Assessed by Domain Delta: how it is measured was reworded
    • DescriptionPatient-Reported Disease Activity & Quality of Life Outcomes Assessed by Facial Disability Index (FDI) for physical facial function: how it is measured was reworded
    • …and 8 more, on the record history on ClinicalTrials.gov ↗
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07086521
Lead sponsor
Restem, LLC.
Collaborators
Solve FSHD
Responsible party
Sponsor
First posted
Jul 25, 2025
Start date
Dec 1, 2025
Primary completion
Sep 2029 (estimated)
Completion
Mar 2030 (estimated)
Last update
Oct 21, 2026

Study contacts

John W Day, MD, PhD
principal investigator · Stanford University, School of Medicine, Neuromuscular Research Division

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion